Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reliant Will Add Antara, Omacor To Cardiovascular Product Line In 2005

Executive Summary

Reliant will launch two recently-approved cardiovascular products, Antara and Omacor, in 2005

You may also be interested in...



GSK Bolsters Cardiovascular Portfolio With Acquisition Of Reliant

GlaxoSmithKline's acquisition of Reliant for $1.65 billion will give the U.K. drug maker access to a growing cardiovascular drug in the U.S., Lovaza. The drug will complement GSK's existing CV portfolio, including the hypertension drug Coreg CR

GSK Bolsters Cardiovascular Portfolio With Acquisition Of Reliant

GlaxoSmithKline's acquisition of Reliant for $1.65 billion will give the U.K. drug maker access to a growing cardiovascular drug in the U.S., Lovaza. The drug will complement GSK's existing CV portfolio, including the hypertension drug Coreg CR

Reliant Omacor Launch Funded Through IPO; Launch Set For Late 2005

Reliant Pharmaceuticals will raise cash through an initial public offering to pay for a sales force expansion for the launch of the triglyercide therapy Omacor

Related Content

Topics

UsernamePublicRestriction

Register

PS045075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel